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The selective serotonin reuptake inhibitor fluoxetine (FLX) is widely
prescribed for depression and anxiety-related disorders. On the other
hand, enhanced serotonergic transmission is known to be classically
related to anxiety. In this study, the effects of acute (5.0 mg/kg) and
chronic (5.0 mg/kg, 22 days) FLX were investigated in both food-
deprived and non-deprived rats tested in the elevated plus-maze.
Significant main effects of the three factors (drug, food condition and
administration regimen) were observed, but no interaction between
them. The administration of either acute or chronic FLX resulted in an
anxiogenic effect, as detected by a significant reduction in the percent-
age of time spent in the open arms and in the percentage of open arm
entries. Food deprivation yielded an anxiolytic-like profile, probably
related to changes in locomotor activity. The administration regimen
resulted in an anxiolytic profile in chronically treated rats, as would be
expected after 22 days of regular handling. The anxiogenic action of
acute FLX is consistent with both its neurochemical and clinical
profile. The discrepancy between the anxiogenic profile of chronic
FLX and its therapeutic uses is discussed in terms of possible differ-
ences between the type of anxiety that is measured in the plus-maze
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Besides being one of the most widely
prescribed drugs for depression, fluoxetine
(FLX) is also used for anxiety-related disor-
ders such as obsessive-compulsive disorder,
panic, social phobia and bulimia nervosa (1-
5). However, the classic hypothesis relating
increased serotonergic function to anxiety
(6,7) predicts that fluoxetine, a selective se-
rotonin reuptake inhibitor (SSRI), would pro-
voke an anxiogenic effect when tested on
animal models. After acute administration,
there is an increase in extracellular serotonin
in several subcortical brain regions due to
reuptake blockade (8,9). Although this ex-
tracellular 5-HT seems to inhibit the firing of
raphe neurons and thus to reduce 5-HT re-
lease from nerve terminals (9), it is often
reported that the initial effect of fluoxetine
administration in humans is an exacerbation
of anxiety (10,11), and this effect has been
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related to the sharp increase in synaptic sero-
tonin concentrations after acute administra-
tion of the drug (7,12). During chronic ad-
ministration there is an increase of extracel-
lular concentrations of 5-HT at cortical and
subcortical levels, and the long-term 5-HT
reuptake blockade provokes desensitization
of somatodendritic 5-HT1A and terminal 5-
HT1B autoreceptors, respectively leading to
a disinhibitory effect on raphe neurons firing
and to reduced feedback inhibition of 5-HT
release (13-15). Both of these neuroadaptive
changes lead to enhanced serotonergic re-
lease and transmission (16,17).
However, the data obtained in animal
studies using SSRI antidepressants are con-
tradictory (12,18,19). Specifically, the evi-
dence of the effect of fluoxetine on animal
models of anxiety is controversial, and stud-
ies on its chronic effects are scarce. Acute
fluoxetine has been shown to promote anxi-
ogenic-like effects in rats tested in the el-
evated plus-maze (20-22), in the hole-board
(20), and in a light-aversion test (20). The
same effects are observed in the novelty-
suppressed feeding model of anxiety (23)
and in the antipredator defensive behavior of
mice (24). Vogels conflict test (22), how-
ever, yielded anxiolytic-like effects in rats,
and so did another light aversion test (25).
Effects of the same nature, albeit weak, were
reported for the shock-induced ultrasonic
vocalization test in rats (19,26). Chronic ad-
ministration of fluoxetine also suggests an
anxiolytic effect of the drug, since it has
been reported to dramatically decrease
flight reactions and defensive attack towards
a predator (24) and to reduce latency to
begin eating in a novel environment (23). On
the other hand, some studies have reported
the absence of either an anxiogenic or an
anxiolytic effect of the drug, administered
acutely or chronically. For example, acute
fluoxetine was inactive in a light aversion
test (19,27) and in the plus-maze (28,29).
When administered chronically at the dose
of 10 mg/kg, it had no effect on a condi-
tioned-fear stress test (30).
The elevated plus-maze is a widely used
animal model of anxiety involving uncondi-
tioned responses based on exploration. Al-
though an anxiogenic effect or a lack of
effect of acute fluoxetine has been found in
some of the studies using the elevated plus-
maze, the chronic effect of the drug on this
model has not been investigated. The pres-
ent experiment was conducted in order to
examine the effect of both acute and chronic
fluoxetine on the elevated plus-maze. A pos-
sible interaction with food deprivation was
also investigated, since a differential effect
of acute versus chronic fluoxetine has been




The subjects were 94 experimentally na-
ive male Wistar rats weighing approximately
300 g at the beginning of the experiment.
They were singly housed in 24.0 x 17.5 x
19.0-cm metal cages and were maintained
on a 12-h dark-light cycle (lights on at 7:00
h) in a temperature- (22  ±  2oC) and humid-
ity- (55% RH) controlled environment. Half
of the subjects were maintained at 80% of
their free-feeding body weight, whereas the
other half had free access to standard rodent
lab food. Water was always available. Ani-
mals were weighed every day except on
weekends.
Apparatus
A standard wooden plus-maze apparatus
consisting of 50 x 10 x 40-cm opposite closed
arms and 50 x 10-cm open arms that radiated
from a central 10 x 10-cm space was used.
The apparatus was elevated to a height of 50
cm above floor level by a single support. The
open arms were surrounded by a 1-cm
translucid Plexiglas ledge, and a dim white
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light (15 W) placed 90 cm above the central
area was the only source of illumination.
Procedure
Experiments were carried out between
9:00 and 17:00 h. Animals were randomly
assigned to two groups, fluoxetine (FLX, N
= 46) and vehicle (VEH, N = 48). The drugs
were administered either acutely or chroni-
cally. In each of these conditions animals
were either food deprived or fed ad libitum.
Thus, FLX and VEH subjects were divided
into 4 subgroups (N = 11-13 each): food
deprived under acute treatment, food de-
prived under chronic treatment, satiated un-
der acute treatment and satiated under chronic
treatment. The eight groups were submitted
to the behavioral procedure in alternate or-
der, so as to counterbalance possible se-
quence effects.
Each subject was placed in the central
area of the maze facing one of the closed
arms, either 60 min after the first injection
(acute treatment) or 60 min after the 22nd
injection (chronic treatment) of fluoxetine
or vehicle, in alternate order. Animals were
observed for 5 min by a trained observer
who sat quietly 1.5 m from the center of the
maze and recorded the time spent in and the
number of entries into each arm. An entry
was recorded when the animals four limbs
had entered an arm. The observer was blind
to the animals condition.
Drugs
Fluoxetine hydrochloride (Lilly, São
Paulo, SP, Brazil) was dissolved in Tween-
80 plus 0.9% NaCl. Daily ip injections of
5 mg/kg were administered for 22 days, at
the same time each day, in the chronic treat-
ment subjects. Rats in the acute treatment
groups received the same dose but only once.
The corresponding treatment was given to
the animals in the control group, which re-
ceived vehicle injections (0.9% NaCl and
Tween-80). All injections were performed
in a different room from that of the plus-
maze testing. The drug dosage was selected
on the basis of its effectiveness on chronic
behavioral procedures such as polydipsia
(31) and stress-induced anhedonia (32).
Data analysis
For each animal, the percent of time spent
in the open arms (100 x open/(open +
closed)), the percent of open arm entries
(100 x open/total), the number of entries into
the closed arms and the total number of
entries (open + closed arms) were computed.
Data were analyzed by a three-factor (drug,
treatment regimen, and food condition) a-
nalysis of variance, with two levels for each
factor (FLX x VEH; chronic x acute; satiated
x deprived).
Results
Analysis of variance showed that there
were no 2-way or 3-way significant interac-
tions between factors. Since 3-way and 2-
way interactions were not significant, main
effects were analyzed. The results are sum-
marized in Figure 1.
There was a significant main effect of
drug condition. Fluoxetine decreased the
percentage of time spent in the open arms
(F(1,86) = 9.825, P<0.01), the percentage of
open arm entries (F(1,86) = 6.884, P<0.01),
total arm entries (F(1,86) = 18.112, P<0.001)
and number of entries into the closed arms
(F(1,86) = 11.085, P<0.001). This main ef-
fect is shown in Figure 1, where it can be
seen that the FLX group means are lower
than the VEH group means in all compari-
sons. This effect occurred independently of
alimentary condition or treatment regimen.
The ANOVA also revealed a significant
main effect of food condition: food depriva-
tion increased the percentage of time spent
in the open arms (F(1,86) = 76.593, P<0.001),
the proportion of open arm entries (F(1,86) =
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41.293, P<0.001), total arm entries (F(1,86)
= 39.316, P<0.001) and the number of en-
tries into the closed arms (F(1,86) = 12.432,
P<0.001). This effect occurred whether the
animals received fluoxetine or vehicle, ei-
ther acutely or chronically.
Furthermore, ANOVA revealed a sig-
nificant main effect of treatment regimen.
The percent of time spent in the open arms
was significantly higher in rats submitted to
a chronic regimen of either FLX or VEH
injections (F(1,86) = 8.896, P<0.01), as also
was the percent of open arm entries (F(1,86)
= 7.362, P<0.01). The treatment regimen did
not affect total number of entries (F(1,86) =
2.871, P>0.05) or number of entries into the
closed arms (F(1,86) = 0.286, P>0.05). This
effect was not related to alimentary condi-
tion or treatment regimen.
Changes in average body weight after
chronic treatment were not significantly dif-
ferent between FLX and VEH in the satiated
food condition. Average (± SEM) body
weights for the VEH and FLX groups in-
creased from 309.2 ± 14.0 and 306.3 ± 17.1
g at the beginning of the experiment to 357.1
± 11.4 and 360.0 ± 13.3 g at the end of the
experiment, respectively (t = 0.10 for initial
weight; t = 0.16 for final weight).
Discussion
Fluoxetine induced an anxiogenic-like
effect in rats tested in the elevated plus-
maze: the drug decreased the proportion of
open arm time and entries, regardless of
whether it was being administered acutely or
chronically, and independently of the sub-
jects being food deprived or satiated. Simul-
taneously it decreased locomotor activity, as
indicated by a reduction in the total number
of arm entries and the number of closed arm
entries. This motor activity reduction by flu-
oxetine has been observed before (20,33).
The anxiogenic-like effect in the plus-maze
has also been reported (20-22), but only after
acute administration of the drug. In the pres-
ent experiment both the chronic and the
acute regimen of administration resulted in
an anxiogenic profile.
The observed anxiogenic effect after both
acute and chronic administration can be seen
in the light of the classic hypothesis relating
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Figure 1 - Effect of fluoxetine on
rats tested on the elevated plus-
maze. Percent time spent in the
open arms, percent entries into
the open arms, total number of
entries and number of entries
into the closed arms are given
for the eight groups in the ex-
periment. “Administration regi-
men” (acute x chronic) and
“food condition” (food deprived
x satiated) are plotted as a func-
tion of the “drug” factor (fluoxe-
tine x vehicle). Significance lev-
els as revealed by a 3-factor
ANOVA are shown in the text.
Data are reported as means ±
SEM. FLX = Fluoxetine, VEH =
vehicle, Ac = acute, Ch =
chronic, Dep = food deprived,
Sat = satiated.
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after acute fluoxetine administration could
be related to the increased extracellular 5-
HT around subcortical structures, observed
after acute administration of SSRIs. The an-
xiogenic effect after chronic treatment would
be consistent with the desensitization of 5-
HT1A autoreceptors and the consequent re-
duction in their inhibitory effects on raphe
activity. It could also be related to the desen-
sitization of 5-HT1B autoreceptors and the
resulting decrease in feedback inhibition of
serotonin release observed in the chronic
condition (9,14,17).
Still, the differential clinical effect of
acute and chronic fluoxetine administration
would lead to the expectation of a differen-
tial effect on the elevated plus-maze indices
of anxiety. In fact, an anxiogenic effect of
fluoxetine would be compatible with clini-
cal reports of increased anxiety during the
first days of drug administration (34), but
would not be consistent with its growing use
in the chronic treatment of anxiety disorders
(4). As the symptoms of anxiety disorders
are heterogeneous and multidetermined, it is
possible that the elevated plus-maze model
is not sensitive to the specific anxiety symp-
toms that show clinical improvement with
chronic fluoxetine. The main criterion for
the use of the elevated plus-maze as an ani-
mal anxiety model is its sensitivity to the
anxiolytic action of benzodiazepines, but it
is known that several anxiety disorders, such
as phobias and panic, are resistant to benzo-
diazepines (35). It is possible that the cat
odor test for phobia (36), or the polydipsia
model for the obsessive compulsive disorder
(31), for example, would be able to detect an
anxiolytic action of chronic fluoxetine in the
rat.
The possibility that the plus-maze results
reported here reflect motor effects of the
drug cannot be discarded. As noted, motor
activity reduction after fluoxetine adminis-
tration has been reported. The effect of flu-
oxetine in the present experiment may have
been confounded by changes in motor be-
havior, as there was a decrease in the total
number of arm entries and in the number of
entries into the closed arms, a reliable index
of locomotor activity in the elevated plus-
maze (37). A model that evaluated both pas-
sive and active avoidance, such as the el-
evated T-maze, would help in dismissing
this possibility (38).
Although fluoxetine has been reported to
produce decreased appetite and food intake
both in humans (39,40) and in rats (41),
subjects in the present study did not show
any changes in body weight after 22 days of
fluoxetine administration. The loss of appe-
tite resulting from fluoxetine treatment would
suggest caution in dealing with anorexic pa-
tients, since although the target of the pre-
scription are emotional effects, the drug can
cause concomitant body weight loss (39).
However, there was no evidence of any in-
teraction between fluoxetine and food depri-
vation on the plus-maze effects within the
parameters of drug administration and food
restriction used. There was, however, a
marked effect of food deprivation on the
indices of the plus-maze: food-deprived ani-
mals showed a marked increase in propor-
tional open arm entries and time, and in the
number of total entries and the number of
entries into the closed arms. The elevated
plus-maze, as an exploratory model of anxi-
ety, relies on the conflict between the ten-
dency to explore a novel environment and
the tendency to avoid open spaces (42,43).
Food deprivation increases the probability
of foraging responses, and this factor, rather
than anxiety reduction, could account for the
high locomotor activity and the increased
tendency of food-deprived rats to enter and
remain in the open spaces in this experiment.
On the other hand, the chronic treatment
regimen resulted in an anxiolytic profile that
was not confounded by locomotor activity.
In fact, daily injections of either drug or
vehicle resulted in subjects scoring propor-
tionally more time and more entries into the
open arms when compared to acutely in-
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jected subjects. Their total number of entries
and number of entries into the closed arms,
however, were not significantly different,
lending support to the hypothesis of an anxi-
olytic effect. This effect probably resulted
from the routine handling necessarily in-
volved in the injection procedure, a factor
known to lead to reduced anxiety as meas-
ured in the elevated plus-maze and other
anxiety paradigms (44,45).
The present results show the anxiolytic
action of handling and suggest an anxio-
genic action of both acute and chronic fluox-
etine on animals tested in the elevated plus-
maze. The anxiogenic action of fluoxetine is
consistent with the neurochemical effects of
the drug on the serotonergic system. These
findings, however, should be extended to
other anxiety models and to other doses of
the drug, especially regarding the chronic
procedure, since lower doses might have
effects on anxiety-related measures but not
on activity parameters.
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